Navigation Links
Isis Reports Positive Results of Phase 2 Study of ISIS 301012 in Heterozygous FH Patients
Date:10/4/2007

- HeFH Patients on Maximally Tolerated Lipid-Lowering Therapies Experienced 46% Further Reductions in LDL-C when Treated with 300 mg/week ISIS 301012

for 13 Weeks - Study Presented in Poster Session Today at DALM Symposium in New York

City - Isis Will Host a Conference Call on Monday, October 8, at 8:00 a.m. E.T.

at http://www.isispharm.com

CARLSBAD, Calif., Oct. 4 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced new results from its Phase 2 clinical trial of ISIS 301012 in patients with heterozygous familial hypercholesterolemia (HeFH) on stable maximally tolerated lipid-lowering therapies presented in a poster session today at the Drugs Affecting Lipid Metabolism (DALM) XVI International Symposium in New York City. These results will also be presented by Dr. John J.P. Kastelein in an oral session at DALM on Saturday at 3:45 p.m. E.T., and Isis will host a conference call Monday morning at 8:00 a.m. E.T. to further discuss the results.

In a randomized, double-blind, placebo-controlled study, HeFH patients being treated with maximally tolerated lipid-lowering therapies were treated with ISIS 301012 for 6 or 13 weeks. Median baseline LDL-C levels for the dose cohorts ranged from 159 - 204 mg/dL. ISIS 301012 add-on treatment produced potent, dose-dependent, prolonged reductions in all atherogenic lipids, and results were consistent with those reported for patients with routine high cholesterol. Furthermore, this study confirmed that ISIS 301012 treatment results in meaningful reductions in Lp(a), another important predictor of
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
9. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
10. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
11. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  Bio-Techne Corporation (NASDAQ: TECH ) announced today ... the new Simple Plex platform through its Proteins Platform ... re-branding of the previously acquired CyPlex instrument platform from ... transformative immunoassay technology which integrates an innovatively designed microfluidic ...
(Date:1/22/2015)... DUBLIN , Jan. 22, 2015 Research and Markets ... of the "Infectious Disease Diagnostics Market by Product, ... report to their offering. , The ... CAGR of 7.9% to reach $18,156.2 million by 2019 ...
(Date:1/22/2015)... The Parenteral Drug Association (PDA) today announced the launch ... Pharmaceutical Manufacturing,s Future. The Manufacturing Science ... , Highlight the ongoing focus PDA has on pharmaceutical and ... filling known gaps in current manufacturing science as well as ...
Breaking Medicine Technology:Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3PDA Launches Manufacturing Science Program(SM) 2PDA Launches Manufacturing Science Program(SM) 3
... MedImmune today announced,that it has initiated a Phase ... healthy children one month to 12 months of age ... is,the most common respiratory infection in infants and can ... is a serious respiratory disease that can have significant ...
... Meeting -, - Conference call to be hosted ... BRANFORD, Conn., Nov. 3 CuraGen Corporation,(Nasdaq: CRGN ... II,trial of CR011-vcMMAE, an antibody-drug conjugate that targets GPNMB, ... Stage IV melanoma.,Dr. Patrick Hwu, Co-Principal Investigator, and Professor ...
Cached Medicine Technology:MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 2CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 3CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 4CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 5CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 6CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma 7
(Date:1/22/2015)... January 22, 2015 Deer Path of Huntley ... a Valentine’s Day Happy Hour from 3 p.m. to 4 p.m. ... Regency Parkway in Huntley, Illinois, serves adults with physical disabilities between ... will include Valentine's Day treats, games and sweetheart-themed karaoke. , For ...
(Date:1/22/2015)... 2015 Woodloch Pines, an all-inclusive family ... by TripAdvisor as the number one best large hotel for ... the world for their annual Travelers’ Choice Awards. , ... The website is home to millions of unbiased and honest ...
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... Dallas, TX (PRWEB) January 22, 2015 ... the issue of experience and person-centeredness in the long-term ... moving towards action across the continuum. The paper, “The ... the Continuum,” engages perspectives and practices of the patient, ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved television ... 32nd Annual Miami Breast Cancer Conference planned ... (PER®) , shares that “a fast-growing, virulent” cancer in ... had not followed up her clean mammogram with an ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 2Health News:TripAdvisor Names Woodloch Pines Best Hotel for Families in America 3Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... has received a five-year, $2.8 million grant from the ... researchers in regions of the world most hard-hit by ... AIDS International Training and Research Program (AITRP), will allow ... there are an estimated 750 new HIV infections every ...
... BOSTON, April 17 Riverside Partners, based in Boston, ... with management to recapitalize IZI Medical Products ("IZI" or ... of high quality medical markers used in Image ... IZI,s products range from fiducial markers, used with MRI, ...
... -- Eli Lilly and Company (NYSE: LLY ... of Lilly,s Canadian affiliate, will join Lilly,s senior management team ... May 1. She succeeds Tony Murphy, Ph. D, who ... years ago, after more than a decade in sales and ...
... PRA International, a leading Clinical Research Organization, announces it ... Congress scheduled for April 21-24, 2009, in Washington, D.C. ... Management at PRA, will chair the session, while Mark ... discuss "Assessment of stakeholders for risk mitigation strategies." The ...
... Access Assurance solutions help MEDNAX increase security and ... Courion(R) Corporation , leaders in access governance, ... has implemented the company,s Enterprise Suite to assure ... approximately 5,000 clinical and administrative employees. MEDNAX ...
... Research Network (MRN) will bring world-leading technology to ... a device for non-invasive measurement of brain activity ... MEG technology to study brain function and disorders ... organization will upgrade to the Elekta Neuromag MEG ...
Cached Medicine News:Health News:Pitt receives $2.8 million to train HIV/AIDS researchers in Mozambique, Brazil and India 2Health News:Riverside Partners Teams with Management to Acquire IZI Medical Products 2Health News:Lilly Names Susan Mahony Senior Vice President of Human Resources 2Health News:PRA International to Present Key Challenges for Safety Professionals at the World Drug Safety Congress: PRA Experts discussing REMS at Washington DC Conference 2Health News:MEDNAX National Medical Group(TM) Uses Courion's Enterprise Suite to Automate Identity and Access Management 2Health News:MEDNAX National Medical Group(TM) Uses Courion's Enterprise Suite to Automate Identity and Access Management 3Health News:Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to the Mind Research Network 2Health News:Elekta Chosen to Deliver Sophisticated Brain Mapping Technology to the Mind Research Network 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: